Navigation Links
Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Date:10/23/2007

th a four day, in-house study period. Post dosing evaluations were conducted for 72 hours in-house, and follow-up visits were scheduled on days seven, 14 and 21.

In this trial, trodusquemine was well tolerated, and there were no serious adverse events reported. In addition to the favorable safety profile of this study, the pharmacokinetic profile of trodusquemine showed a consistent pattern with minimal subject-to-subject variability and linearity across the range of doses studied.

"The safety, tolerability and pharmacokinetics of trodusquemine observed in this study are consistent with the results achieved in preclinical studies," stated Michael Gast, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Genaera. "We look forward to advancing trodusquemine through the clinic in our next set of clinical trials as we study patients with both obesity and type 2 diabetes so that we may potentially provide a monotherapy option for patients afflicted by these disorders."

The Company expects to conduct its second ascending single dose Phase 1 clinical trial (Study MSI-1436C-103) of trodusquemine in obese type 2 diabetics. The trial will evaluate the PK and safety of trodusquemine in this population as well as provide the first opportunity to study short-term glucose control indices, glucose tolerance and insulin sensitivity.

The poster presented at NAASO, "First in Human Use of MSI-1436 (Trodusquemine) a Centrally and Peripherally Acting Selective PTP1B Inhibitor" will be presented today from 9:00 a.m. to 2:30 p.m., Central Time. Clinical researchers from Genaera will be available at the poster from 1:00 p.m. to 2:30 p.m., Central Time to discuss the poster presentation.

About Trodusquemine

Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 a
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- MHG Medical Management Services, a ... Medical Equipment and X-ray Annual Inspection & ... to the cruise industry,s unique requirements.  MHG Medical,s ... propose that they should develop a new service. ... intended to create standardized processes and raise standards, ...
(Date:7/29/2014)... July 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... report its second quarter 2014 financial results after the ... will then host a live conference call and webcast ... update Thursday morning, August 7, 2014 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1907 ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... NanoBio Corporation,announced today that it has seen ... 2 study of NB-002, a topical lotion for ... results clearly,justify completing the study, according to NanoBio ... grow out a clear nail after,successfully treating the ...
... March 20 PLC Systems Inc.,(Amex: PLC ... approval from,the U.S. Food and Drug Administration (FDA) ... study the effectiveness of the Company,s RenalGuard,Therapy(TM) and ... Mark R. Tauscher, President and Chief Executive ...
Cached Medicine Technology:NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 3PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 4
(Date:7/30/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... iFitDress.com, a well-known wedding dress manufacturer and retailer, has unveiled ... from this, it has announced that all of them are ... of its old and new clients may now access the ... “We are pleased to release the new collection of satin ... of amazing items. It is true that our satin bridal ...
(Date:7/29/2014)... 2014 Dignity Sciences Limited, a privately ... a Phase I trial with DS107G, an oral formulation ... was a randomized, placebo-controlled, double-blind, single-ascending and multiple dose ... and effect of food on DS107G in healthy subjects. ... of DGLA following both single and multiple oral doses ...
(Date:7/29/2014)... discovered a chemical alteration in a single human gene ... studies, could give doctors a simple blood test to ... The discovery, described online in The American Journal ... involved in the function of the brain,s response to ... might otherwise be an unremarkable reaction to the strain ...
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps ... that he cured his condition with the use of this ... of his experience. , He claimed that he was ... just 4 days. Since his method turned out being so ... around the world. , The Nasal Polyps Treatment Miracle ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2
... the US Food and Drug Administration gave its approval ... in the treatment of chronic Hepatitis B// (HBV). Clinical studies ... effects and is usually well tolerated. ,Hepatitis B ... 70,000 Americans every year. It is a serious illness and ...
... workplace cafeterias and vending machines, to understand the nature of ... in the levels of obesity, this is certainly called for, ... diseases. ,The Ministry of Health will keep ... next two years to ascertain the types of food enabled ...
... vaccine are underway in Mozambique, certainly not a farfetched goal ... The production// of the vaccine is estimated at about $60-million. ... addressing a gathering of health officials said 'We think the ... tests in Manhica (north of the capital Maputo) are effective. ...
... boy died of dengue fever here Wednesday, taking the toll ... as officials maintained that the number of cases had dropped ... Pradesh, died at the All India Institute of Medical Sciences ... in a critical condition. , ,"His condition was deteriorating ...
... light on the alarming trend among teenage girls taking to smoking//, ... to dispel the myth that smoking helps in controlling weight. , ... much the same way as their peers who do not smoke. ... which deserves to be puffed out. , ,Dr. Louise Pilote, ...
... dose of folic acid every day could have better chance of ... a form of vitamin B is used in our bodies to ... her body before she is pregnant, it can help prevent major ... latest study involving more than 18,000 women for the first time ...
Cached Medicine News:Health News:13-Year-Old Boy Is Latest Dengue Victim; Delhi Toll 47 2Health News:Folic Acid Supplements Could Help Conception 2
... utilizes allele-specific primer combinations in the PCR ... that only primers whose sequence is completely ... converted by the polymerase into PCR products. ... product. Using the Biotest SSP Kit Systems, ...
... The freezer is constructed with built-in bags ... the plasma bags are placed without contacting the ... and heavy inserts. This device ensures easy handling ... immersed plasma bags so that the relatively hot ...
Helmer offers Plasma Storage Freezer lines, the i.Series ipf 125-8. It is Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost tim...
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...
Medicine Products: